-
公开(公告)号：US20250122241A1
公开(公告)日：2025-04-17
申请号：US18567472
申请日：2022-06-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： TAO WANG
IPC: C07K7/54
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PDL1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
2.发明申请公开(公告)号：US20130289046A1
公开(公告)日：2013-10-31
申请号：US13858624
申请日：2013-04-08
Applicant: Bristol-Myers Squibb Company
Inventor： TAO WANG , Zhongxing Zhang , Nicholas A. Meanwell , John F. Kadow , Zhiwei Yin , Qiufen May Xue , Alicia Regueiro-Ren , John D. Matiskella , Yasutsugu Ueda
IPC: A61K31/496 , A61K45/06
CPC classification number: C07D471/04 , A61K31/496 , A61K45/06 , C07D491/048
Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
-
公开(公告)号：US20240261367A1
公开(公告)日：2024-08-08
申请号：US18554675
申请日：2022-04-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： TAO WANG
CPC classification number: A61K38/12 , A61K47/543 , A61K47/545 , A61K47/60
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PDL1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20160075703A1
公开(公告)日：2016-03-17
申请号：US14878270
申请日：2015-10-08
Applicant: Bristol-Myers Squibb Company
Inventor： TAO WANG , Zhongxing Zhang , Nicholas A. Meanwell , John F. Kadow , Zhiwei Yin , Qiufen May Xue , Alicia Regueiro-Ren , John D. Matiskella , Yasutsugu Ueda
IPC: C07D471/04 , C07D491/048
CPC classification number: C07D471/04 , A61K31/496 , A61K45/06 , C07D491/048
Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
-
公开(公告)号：US20230151059A1
公开(公告)日：2023-05-18
申请号：US17995196
申请日：2021-03-30
Applicant: Bristol-Myers Squibb Company
Inventor： TAO WANG
IPC: C07K7/56 , C07D513/22 , A61P35/00 , A61P31/04 , A61P31/12
Abstract: In accordance with the present disclosure, compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
-
Patent Agency Ranking
公开(公告)号：US20160152615A1
公开(公告)日：2016-06-02
申请号：US15015712
申请日：2016-02-04
Applicant: Bristol-Myers Squibb Company
Inventor： TAO WANG , Zhongxing Zhang , Nicholas A. Meanwell , John F. Kadow , Zhiwei Yin , Qiufen May Xue , Alicia Regueiro-Ren , John D. Matiskella , Yasutsugu Ueda
IPC: C07D471/04
CPC classification number: C07D471/04 , A61K31/496 , A61K45/06 , C07D491/048
Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
-
公开(公告)号：US20240327389A1
公开(公告)日：2024-10-03
申请号：US18499791
申请日：2022-05-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： TAO WANG , Zhongxing Zhang , Zhiwei Yin
IPC: C07D405/14 , A61K31/395 , A61K31/444 , A61K31/4525 , A61K31/454 , A61K31/4545 , A61K31/553 , C07D211/56 , C07D401/12 , C07D401/14 , C07D405/12 , C07D413/14
CPC classification number: C07D405/14 , A61K31/444 , A61K31/4525 , A61K31/454 , A61K31/4545 , A61K31/553 , A61K31/5545 , C07D211/56 , C07D401/12 , C07D401/14 , C07D405/12 , C07D413/14
Abstract: The present disclosure generally relates to lactone and lactam containing compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds. and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20160159769A1
公开(公告)日：2016-06-09
申请号：US14771914
申请日：2014-03-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： TAO WANG , CHRISTOPHER ALLARD
IPC: C07D401/12 , A61K45/06 , C07D413/14 , C07D417/14 , A61K31/5377 , A61K31/506 , C07D401/14
CPC classification number: C07D401/12 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D413/14 , C07D417/14
Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
Abstract translation: 本公开提供式I化合物，包括药学上可接受的盐，以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。
-
公开(公告)号：US20150320757A1
公开(公告)日：2015-11-12
申请号：US14762542
申请日：2014-01-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： TAO WANG , Zhongxing Zhang , Ying Han , Zhiwei Yin , Paul Michael Scola
IPC: A61K31/53 , C07D403/12 , A61K31/551 , C07D251/52 , A61K45/06
CPC classification number: A61K31/53 , A61K31/551 , A61K45/06 , C07D251/52 , C07D403/12 , C07D403/14
Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
Abstract translation: 除了使用这些化合物的组合物和方法之外，还列举了式I化合物，包括其药学上可接受的盐。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。
-
10.发明申请公开(公告)号：US20140135335A1
公开(公告)日：2014-05-15
申请号：US14073963
申请日：2013-11-07
Applicant: Bristol-Myers Squibb Company
Inventor： TAO WANG , Zhiwei Yin , Paul Michael Scola
IPC: C07D487/10 , A61K45/06 , A61K31/53
CPC classification number: C07D487/10 , A61K31/53 , A61K45/06 , A61K2300/00
Abstract: Compounds of Formula I, including pharmaceutically acceptable salts, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:
Abstract translation: 包括药学上可接受的盐的式I化合物以及含有这些化合物的组合物具有抗丙型肝炎病毒（HCV）的活性，并且可用于治疗HCV感染者：
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.022 seconds)
